+ Filter



LY2119620

Anti-LY2119620 Products
- Recombinant Anti-LY2119620 Antibody (MOB-635)
-
- Derivation: Mouse
- Type: IgG
- Application: WB, IF, FuncS
-
- Derivation: Human
- Type: IgG
- Application: WB, Neut, FuncS
- Recombinant Human Anti-LY2119620 Antibody Fab Fragment (MHH-635-F(E))
-
- Derivation: Human
- Type: Fab
- Application: ELISA, WB, FC, FuncS
- Recombinant Human Anti-LY2119620 Antibody scFv Fragment (MHH-635-S(P))
-
- Derivation: Human
- Type: scFv
- Application: FC, ELISA, FuncS
- Recombinant Anti-LY2119620 Antibody Fab Fragment (MOB-635-F(E))
-
- Derivation: Mouse
- Type: Fab
- Application: FC, ELISA, FuncS
- Recombinant Anti-LY2119620 Antibody scFv Fragment (MOB-635-S(P))
-
- Derivation: Mouse
- Type: scFv
- Application: RIA, ELISA, FuncS
View More Products
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
LY2119620 is a specific, and allosteric agonist of human M2 and M4 muscarinic acetylcholine receptors.
LY2119620 displays modest allosteric agonism and positively modulates the functional G protein–signaling ability of an agonist at the M2/M4 receptor subtypes by placing the M2 and M4 receptors into an active G protein–bound state. LY2119620 enhances the potency of three muscarinic acetylcholine receptor agonists, ACh, Oxo-M and iperoxo. [3H]LY2119620 can be used as a probe for the human M(2) and M(4) muscarinic receptor allosteric binding sites.
LY2119620 displays modest allosteric agonism and positively modulates the functional G protein–signaling ability of an agonist at the M2/M4 receptor subtypes by placing the M2 and M4 receptors into an active G protein–bound state. LY2119620 enhances the potency of three muscarinic acetylcholine receptor agonists, ACh, Oxo-M and iperoxo. [3H]LY2119620 can be used as a probe for the human M(2) and M(4) muscarinic receptor allosteric binding sites.